Technomad Selected as Electronic Data Capture Partner for Investigational New Drug Application for COVID-19

BONITA SPRINGS, Fla., May 26, 2020 /PRNewswire-PRWeb/ -- Technomad, an innovative technology solutions company, today announced that its proprietary HIPAA-compliant cloud-based electronic data capture (EDC) platform, ChartPad®, was selected by Organicell Regenerative Medicine, Inc for the study of two FDA-approved Emergency Single Patient Compassionate Use trials.

The study is taking place at Landmark Hospitals, a state-of-the-art hospital system of six long-term acute care hospitals across the Southeast. Two recovering COVID-19 patients in the ICU setting at Landmark Hospital of Athens, GA were treated last week with the first doses of OrganicellTM Flow Allogenic Amniotic fluid. Study data was documented in real time directly into the ChartPad® EDC platform.

"ChartPad provides an easy-to-use platform for quick training of clinical staff and minimizes disruption of workflows in the ICU setting," states Dr. William Kapp, Founder and Chairman of Landmark Hospitals.

ChartPad® provides rapid deployment of study case report forms (CRFs) in a cloud-based format for collection and management of data and is integrated with laboratory systems to streamline results entry and reduce documentation errors. ChartPad® is in use by the Primary Investigators, Co-Investigators, the Clinical Trial Management team, Clinical Trial Site Coordinators, and the Data Collection and Analysis team for on-demand access to documentation, trending, and analysis of the COVID-19 research data.

About Technomad:
Founded in 2012, Technomad is a technology solutions company specializing in healthcare IT and application development services. Based in Bonita Springs, FL, Technomad is the developer of ChartPad®, a cloud-based electronic healthcare record (EHR) and Electronic Data Capture (EDC) system. Technomad provides expertise, guidance, and support on all aspects of IT infrastructure, computing, and software systems. For more information, please visit

About Landmark Hospitals:
Landmark provides solutions for patients who face a hospital discharge, yet still require acute medical care. These patients require a higher level of care for a longer period than the average hospital offers; but they are not yet ready to transfer to a sub-acute care facility. Landmark brings exciting new technologies and experienced management for the primary task of providing patients with the best medical care available as they continue their journey toward healing. For more information regarding Landmark Hospitals, visit

About Organicell Regenerative Medicine, Inc:
Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical company that harnesses the power of exosomes to develop innovative biological therapeutics for the treatment of degenerative diseases. The company's proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. Based in South Florida, the company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Mari Mitrani, Chief Scientific Officer. To learn more, please visit

SOURCE Technomad